설명

지난 10년 동안, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. A study by StrategyHelix indicates that the global liquid biopsy market is expected to increase by US$ 6,579.5 백만에서 2022 에게 2028, 의 CAGR 획득 16.1% 예측 기간 동안.

이 보고서는 기간 동안 최신 시장 규모 데이터를 제공합니다. 2018-2021 그리고 예측 2028 covering key market aspects like sales value for liquid biopsy. The global liquid biopsy market is segmented on the basis of therapy, 애플리케이션, biomarker type, 기술, 및 지역. Based on therapy, the global liquid biopsy market is categorized into oncology, noninvasive prenatal testing (NIPT), 다른 사람 (e.g. organ transplant). The NIPT segment captured the largest share of the market in 2021. 신청을 기준으로, the global liquid biopsy market has been segmented into diagnosis, early detection/screening, 모니터링, therapy guidance. The early detection/screening segment held the largest share of the global liquid biopsy market in 2021 예측 기간 동안 점유율을 유지할 것으로 예상됩니다.. By biomarker type, the global liquid biopsy market has been segmented into cell-free nucleic acids, circulating tumor cells, 다른 사람. ~ 안에 2021, the cell-free nucleic acids segment made up the largest share of revenue generated by the liquid biopsy market. Based upon technology, the global liquid biopsy market is categorized into next-generation sequencing (NGS), polymerase chain reaction (PCR), 다른 사람. 이들 중, the next-generation sequencing (NGS) segment was accounted for the highest revenue generator in 2021. 지리학적 측면에서, the global liquid biopsy market has been segmented into Asia Pacific, 유럽, 북아메리카, 세계의 나머지 (열).

The global liquid biopsy market is highly competitive. Top players covered in Global Liquid Biopsy Market Study are Adaptive Biotechnologies Corp., Agilent Technologies Inc., Amoy Diagnostics Co. (주), Becton Dickinson and Company, Berry Genomics Co. (주), BGI 그룹, Biocartis Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Rad Laboratories Inc., Bio-Techne Corp., CareDx Inc., Danaher Corp., Eurofins Scientific, EXACT Sciences Corporation, Illumina Inc., Koninklijke Philips N.V., Merck KGaA, 무수한 유전학 Inc., NeoGenomics Laboratories Inc., OncoCyte Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Qiagen N.V., Roche Holding AG, Takara Bio Inc., Thermo Fisher Scientific Inc., VolitionRx Limited.

이 보고서는 이 업계에서 활동하는 회사 및 조직에 매우 귀중한 리소스입니다.. It provides a cohesive picture of the liquid biopsy market to help drive informed decision making for industry executives, 정책 입안자, 학생, 및 분석가.

보고 범위

Therapy: oncology, noninvasive prenatal testing (NIPT), 다른 사람 (e.g. organ transplant)
애플리케이션: 진단, early detection/screening, 모니터링, therapy guidance
Biomarker type: cell-free nucleic acids, circulating tumor cells, 다른 사람
기술: next-generation sequencing (NGS), polymerase chain reaction (PCR), 다른 사람
지역: 아시아 태평양, 유럽, 북아메리카, 세계의 나머지 (열)
년 고려: 이 보고서는 기간을 다룹니다 2018 에게 2028

이해관계자를 위한 주요 이점

– Get a comprehensive picture of the global liquid biopsy market
– 성장 분야 및 투자 동향 파악

목차

부분 1. 소개
– 연구 범위
– 공부 기간
– 지리적 범위
– 연구 방법론
부분 2. Liquid biopsy market overview
부분 3. Market breakdown by therapy
– 종양학
– Noninvasive prenatal testing (NIPT)
– 기타 (e.g. organ transplant)
부분 4. 애플리케이션별 시장 분석
– Diagnosis
– Early detection/screening
– Monitoring
– Therapy guidance
부분 5. Market breakdown by biomarker type
– Cell-free nucleic acids
– Circulating tumor cells
– 기타
부분 6. Market breakdown by technology
– Next-generation sequencing (NGS)
– Polymerase chain reaction (PCR)
– 기타
부분 7. 지역별 시장 분석
– 아시아 태평양
– 유럽
– 북아메리카
– 세계의 나머지 (열)
부분 8. 주요 기업
– Adaptive Biotechnologies Corp.
– Agilent Technologies Inc.
– Amoy Diagnostics Co., (주).
– 벡톤, 디킨슨 앤 컴퍼니
– Berry Genomics Co., (주).
– BGI 그룹
– Biocartis Group
– Biocept, 주식회사.
– Biodesix, 주식회사.
– Biolidics Limited
– Bio-Rad 연구소, 주식회사.
– Bio-Techne Corp.
– CareDx, 주식회사.
– Danaher Corp.
– Eurofins Scientific
– EXACT Sciences Corporation
– Illumina, 주식회사.
– Koninklijke 필립스 N.V.
– Merck KGaA
– Myriad Genetics, 주식회사.
– NeoGenomics Laboratories, 주식회사.
– OncoCyte Corporation
– Oxford Nanopore Technologies Limited
– 캘리포니아 태평양 생명과학, 주식회사.
– Qiagen N.V.
– Roche Holding AG
– Takara Bio Inc.
– 써모 피셔 사이언티픽(주).
– VolitionRx Limited
스트래티지헬릭스 소개
부인 성명